Formycon Reports Positive Phase III Data On Ustekinumab
Company Is Looking For Marketing Partner On Stelara Biosimilar By Year End
Formycon has reported positive preliminary efficacy and safety data from the Phase III program for its FYB202 proposed ustekinumab biosimilar rival to Stelara.
